BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37743339)

  • 21. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report.
    Serrallach BL; Tran BH; Bauer DF; Mohila CA; Adesina AM; McGovern SL; Lindsay HB; Huisman TA
    Neuroradiol J; 2022 Oct; 35(5):634-639. PubMed ID: 34989626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
    Damodharan S; Helgager J; Puccetti D
    Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
    Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
    Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas.
    Kazarian E; Marks A; Cui J; Darbinyan A; Tong E; Mueller S; Cha S; Aboian MS
    Sci Rep; 2021 Jul; 11(1):14377. PubMed ID: 34257334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
    Hu W; Duan H; Zhong S; Zeng J; Mou Y
    J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
    Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
    Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
    Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
    Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
    Lavrador JP; Reisz Z; Sibtain N; Rajwani K; Baig Mirza A; Vergani F; Gullan R; Bhangoo R; Ashkan K; Bleil C; Zebian B; Clark B; Laxton R; King A; Bodi I; Al-Saraj S
    Acta Neurochir (Wien); 2023 Jun; 165(6):1615-1633. PubMed ID: 36929449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient.
    Fujioka Y; Hata N; Hatae R; Suzuki SO; Sangatsuda Y; Nakahara Y; Mizoguchi M; Iihara K
    Neuropathology; 2020 Feb; 40(1):99-103. PubMed ID: 31762138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cortical myelin and thickness mapping provide insights into whole-brain tumor burden in diffuse midline glioma.
    Zhang S; Yang X; Tan Q; Sun H; Chen D; Chen Y; Zhang H; Yang Y; Gong Q; Yue Q
    Cereb Cortex; 2024 Jan; 34(1):. PubMed ID: 38112602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
    Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
    Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tectal Low-Grade Glioma with H3 K27M Mutation.
    Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
    World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric diffuse hemispheric glioma H3 G34-mutant with gains of the BRAF locus: An illustrative case.
    Marlow C; Cuoco JA; Hoggarth AR; Stump MS; Apfel LS; Rogers CM
    Rare Tumors; 2023; 15():20363613231168704. PubMed ID: 37056711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adult spinal cord diffuse midline glioma, H3 K27-altered mimics symptoms of central nervous system infection: a case report.
    Chen X; Li Y; Bu H; Zou Y; He J; Liu H
    Front Neurol; 2023; 14():1097157. PubMed ID: 37396765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
    Wood MD; Beadling C; Neff T; Moore S; Harrington CA; Baird L; Corless C
    Acta Neuropathol Commun; 2023 Sep; 11(1):143. PubMed ID: 37670377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.